Pre-operative Alcohol Skin Solutions in Fractured Extremities

NCT03523962 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 8485

Last updated 2024-10-04

Study results available
· View outcomes & findings →

Summary

The prevention of infection is an important goal influencing peri-operative care of extremity fracture patients. Standard practice in the operative management of extremity fractures includes sterile technique and pre-operative skin preparation with an antiseptic solution. The available solutions kill bacteria and decrease the quantity of native skin flora, thereby decreasing surgical site infection (SSI). While there is extensive guidance on specific procedures for prophylactic antibiotic use and standards for sterile technique, the evidence regarding the choice of antiseptic skin preparation solution is very limited for extremity fracture surgery.

Conditions

  • Surgical Site Infection
  • Unplanned Fracture-Related Reoperation
  • Open Appendicular Fracture
  • Closed Lower Extremity Fracture
  • Pelvic Fracture

Interventions

DRUG

DuraPrep

The iodine-based treatment intervention is an antiseptic solution comprised of iodine povacrylex (0.7% free iodine) in 74% isopropyl alcohol. 3M™ DuraPrep™ \[3M Health Care, St Paul, MN\], will be the commercial product used.

DRUG

ChloraPrep

The CHG intervention is an antiseptic solution comprised of 2% CHG in 70% isopropyl alcohol. ChloraPrep® \[CareFusion Inc., Leawood, KS, USA\] will be the product used.

Sponsors & Collaborators

  • McMaster University

    collaborator OTHER
  • Patient-Centered Outcomes Research Institute

    collaborator OTHER
  • University of Maryland, Baltimore

    lead OTHER

Principal Investigators

  • Gerard Slobogean, MD · University of Maryland, Baltimore

  • Sheila Sprague, PhD · McMaster University

  • Mohit Bhandari, MD · McMaster University

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-08-21
Primary Completion
2023-03-15
Completion
2024-02-02
FDA Drug
Yes

Countries

  • United States
  • Canada

Study Locations

More Related Trials

Entities

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03523962 on ClinicalTrials.gov